title: Toxicity and prognosis in overweight and obese women with lung cancer receiving carboplatin-paclitaxel doublet chemotherapy.
abstract: We retrospectively analyzed overdosing-related toxicity and prognosis in 127 women with lung cancer receiving carboplatin (6AUC) estimated by the Cockcroft-Gault formula using actual body weight and paclitaxel (200 mg/m(2)). Between the body mass index (BMI) > 25 group (n = 42) and the BMI ≤ 25 group (n = 85), there was no difference in dose intensity of carboplatin (122 mg/m(2)/week vs. 124 mg/m(2)/week, p = .323), median overall survival (285 days vs. 282 days, p = .820), and toxicity, except Grade 4 neutropenia in the second cycle. Women with BMI > 25 did not have an increased risk of toxicity because of an appropriate dose reduction.
authors.affiliation: Department of Respiratory Medicine, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan. kskkswbr@kumamoto2.hosp.go.jp
authors.forename: Kosuke
authors.initials: K
authors.lastname: Kashiwabara
authors.forename: Hiromi
authors.initials: H
authors.lastname: Yamane
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Tanaka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D015992:Body Mass Index; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000150:complications / Q000188:drug therapy; D062787:Drug Overdose; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009765:Obesity / Q000150:complications*; D050177:Overweight / Q000150:complications*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk
chemical_list: D016190:Carboplatin; D017239:Paclitaxel